SRC:MixSentence, IDs:1CB5D976;485FA936;3AD5669B;AF24C528;430C4AF5;DE757C7F;4F45A2FE;24F2A662;99219F16;FC8C0D50;63624C40;F78D37A9;1F46BF33;4F03F29E;C54A2492;1FADB78C;0ECB4049;04EFBA12;6B520626;E73F66B8;EA15627F;F3096291;39C9A45B;CEC0943E;C0692D6E;48263096;62457DA4
If this is where clinical research is headed, that would be a terrible negative trajectory," he said. Dr. Topol - who drew attention last year with a finding that Celebrex and its competitor, Vioxx, appeared to raise the risk of heart attacks - said the Bextra studies did not include enough patients to justify drawing a broad conclusion. The average age of patients in the study, 23, did not represent the population likely to take the drug, he added. Yet through publication in the leading dental journal, the research helped Bextra's marketers shift attention away from the F.D.A.'s negative findings. Because of confidentiality rules, the F.D.A. cannot release any information about the earlier pain studies that failed to sway regulators. "Even though the study lacked some important proof, the real problem is that in the dental literature, this will be read," Dr. Topol said. "And dentists, who have to deal with trying to prevent or modulate pain, will be impressed." Judy Glova, a spokeswoman for Pharmacia, said the drug company stood behind the design and conclusions of the Scirex studies. Pharmacia was not trying to bypass the regulatory process, she said, adding that the company is in discussions with regulators to have Bextra approved for acute pain. Scirex executives did not return repeated phone calls. Editors at The Journal of the American Dental Association said the Scirex article was reviewed by at least three scientists. One reviewer, Dr. Paul A. Moore, an associate editor of the journal, said the study was "carefully designed and rigorously performed." But Dr. Moore said he would have recommended that the journal reject the paper had he known that Bextra was not approved for acute pain. The Bextra episode is just one example of the changing face of drug research. In the early 1990's, about 75 percent of the drug industry's clinical research dollars went to universities, according to a study by CenterWatch, a company that tracks clinical trials. By 2000, just 34 percent went to academic institutions, while the rest went to investigators working under the direction of either a private research firm like Scirex or a pharmaceutical company. Omnicom says it has no control over Scirex. "We have nothing to do with the design of clinical studies," said Pat Sloan, an Omnicom spokeswoman. Yet when the ad agency paid $20 million for part-ownership of Scirex in 1999, a top Omnicom executive, Thomas L. Harrison, said he expected Scirex's research to produce positive results for drug company clients - results that would help speed new-drug applications, or N.D.A.'s, to the F.D.A. "Our goal," he said, "is to help ensure that all clinical studies and each patient accrued into a study can be assessed to support the N.D.A.

vikingkayaks.co.nzSRC:MixSentence, IDs:4001EF39;04EFBA12;D70F9551;FA6D331A;90C3508B;8655D580;723A698E;5AD61E1B;18073D02;41A18EFB;6B520626;8A521820;D7418648;60570297;0B4D3441;183CDF30;65591CD5;A2107323;878FED22;DCA74BA0;4783AC6E;DDF36E88;C5FF299B;176F41BE;F42FD8B5;BADFE870;FFB14DFC;ED732AD7;E39BB509;4DE6ED1A;9C9F8712;BCA08FF8;BF1C8051;7C03439F;A280F89D;07405E10;3EEB98CB;03EA264C;4BCDBA06;CE3E58BF;4CDE9612;AA48DA5E;167CCA31;AD2F6436;F78D37A9;75B58E06;1E951DB3;7D554A60
They use funny memes to get their ideas across but also do nice recap posts like the one above where they discuss their value proposition. And it’s wisdom: these aren’t ideas that you can search for on the internet; these are deep reflections on those ideas from a smart person who cares about them. Don’t let the title deceive you -- this book should be mandatory reading for anyone who creates for others, not just musicians. Don’t let the title fool you. Music is the title of the book, however, it could also say, your painting, or your basket weaving or printmaking. If that doesn’t convince you that you’ll love this book, gosh, then maybe it’s just not for you? The rest of the book, until page 132 is full of stories from Derek’s life on how he pursued his music. Each chapter was full of insights and actionable ideas. I’m not a musician but I’ve been able to apply the ideas to my work. If you have any queries pertaining to in which and how to use submit directory, you can get hold of us at our page. Everyone from songwriters to artists will have a whole new view of the music business and how best to use your talents, your time, and all your resources after absorbing the many helpful and thought-provoking ideas and suggestions contained in this book.

netzero.netMore often than not, we have spent time to vet a high-quality service and secured a discount on behalf of our Members. Be helpful to others in any kind of way, your time to receive help will come too. Because of Darryn Duchon's limited advertising and efficient business operations, he can save you money compared to what other firms will charge. I frequently reread this book whenever I need to realign my values when it comes to business. No other gifted book has returned such heartfelt appreciation. This book has become a bible for me of sorts. If you’re serious about actually making a living as an artist, this book helps you get in the drivers seat of your career instead of sitting around waiting to be discovered. However, this is my page, so I get to say what I think, and I think that a royalty rate of less than 15% is low. And I think the best part about it is that it applies to any artist-- not just musicians. Make sure you think through each of your objectives logically. It is even possible to demand a European solution, or to create requirements that make it very hard for surveillance-capitalist suppliers to deliver a compliant bid.